Pneumocystis pneumonia in children

Vasilios Pyrgos, Shmuel Shoham, Emmanuel Roilides, Thomas J. Walsh

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised children with quantitative and qualitative defects in T lymphocytes. At risk are children with lymphoid malignancies, HIV infection, corticosteroid therapy, transplantation and primary immunodeficiency states. Diagnosis is established through direct examination or polymerase chain reaction (PCR) from respiratory secretions. Trimethoprim-sulphamethoxazole is used for initial therapy in most patients, while pentamidine, atovaquone, clindamycin plus primaquine, and dapsone plus trimethoprim are alternatives. Prophylaxis of high-risk patients reduces but does not eliminate the risk of PCP. Improved understanding of the pathogenesis of PCP is important for future advances against this life-threatening infection.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalPaediatric Respiratory Reviews
Issue number4
StatePublished - Dec 2009
Externally publishedYes


  • Corticosteroids
  • Immunocompromised children
  • Pneumocystis pneumonia (pcp)
  • T-lymphocytes
  • Trimethoprim-sulphamethoxazole

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Pneumocystis pneumonia in children'. Together they form a unique fingerprint.

Cite this